NYSE · STEHealthcareOrthopedic & Surgical Supplies

STERIS financials

$210.65−0.17%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ1 '27
Jun 30
Q4 '26
Mar 31
Q3 '26
Dec 31
Q2 '26
Sep 30
Q1 '26
Jun 30
Q4 '25
Mar 31
Q3 '25
Dec 31
Q2 '25
Sep 30
Q1 '25
Jun 30
Q4 '24
Mar 31
Q3 '24
Dec 31
Q2 '24
Sep 30
Revenue$1.49B$1.59B$1.50B$1.46B$1.39B$1.48B$1.37B$1.33B$1.28B$1.42B$1.30B$1.24B
Gross profit$684.2M$697.2M$655.5M$645.9M$628.0M$641.2M$610.4M$578.8M$572.4M$582.9M$560.0M$546.2M
Gross margin45.8%43.9%43.8%44.2%45.1%43.3%44.5%43.6%44.7%41.1%43.2%44.1%
Operating income$286.2M$316.9M$273.3M$265.8M$246.0M$216.2M$245.3M$219.7M$185.5M$220.3M$226.5M$191.6M
Net income$200.1M$220.2M$192.9M$191.9M$177.4M$145.6M$173.5M$150.0M$145.4M-$1.4M$140.7M$115.3M
Net margin13.4%13.9%12.9%13.1%12.8%9.8%12.7%11.3%11.4%−0.1%10.8%9.3%
Diluted EPS$2.04$2.23$1.96$1.94$1.79$1.47$1.75$1.51$1.46$-0.01$1.42$1.16
EBITDA$410.0M$440.0M$395.7M$389.7M$367.2M$353.8M$373.4M$337.8M$323.9M$410.6M$367.1M$343.8M
Operating cash flow$367.1M$335.5M$298.2M$287.7M$420.0M$260.9M$332.7M$250.8M$303.7M$254.8M$291.2M$146.1M
Free cash flow$279.6M$245.3M$199.5M$201.2M$326.4M$190.0M$243.5M$148.9M$195.6M$163.3M$172.3M$62.8M
Diluted shares97.9M98.6M98.6M98.8M98.8M98.9M98.9M99.2M99.4M99.6M99.4M99.4M

Balance sheet

Period endJun 30Mar 31Dec 31Sep 30Jun 30Mar 31
Cash & equivalents$482.3M$439.6M$423.7M$319.2M$279.7M$171.7M
Short-term investments$0.00$0.00$0.00$0.00$0.00$0.00
Total debt$1.89B$1.93B$1.90B$1.90B$1.90B$2.04B
Total assets$10.74B$10.74B$10.59B$10.41B$10.40B$10.15B
Total liabilities$3.51B$3.54B$3.42B$3.39B$3.44B$3.53B
Shareholders' equity$7.22B$7.20B$7.17B$7.02B$6.97B$6.62B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology